Unknown

Dataset Information

0

Subretinal AAV delivery of RNAi-therapeutics targeting VEGFA reduces choroidal neovascularization in a large animal model.


ABSTRACT: Neovascular age-related macular degeneration (nAMD) is a frequent cause of vision loss among the elderly in the Western world. Current disease management with repeated injections of anti-VEGF agents accumulates the risk for adverse events and constitutes a burden for society and the individual patient. Sustained suppression of VEGF using gene therapy is an attractive alternative, which we explored using adeno-associated virus (AAV)-based delivery of novel RNA interference (RNAi) effectors in a porcine model of choroidal neovascularization (CNV). The potency of VEGFA-targeting, Ago2-dependent short hairpin RNAs placed in pri-microRNA scaffolds (miR-agshRNA) was established in vitro and in vivo in mice. Subsequently, AAV serotype 8 (AAV2.8) vectors encoding VEGFA-targeting or irrelevant miR-agshRNAs under the control of a tissue-specific promotor were delivered to the porcine retina via subretinal injection before CNV induction by laser. Notably, VEGFA-targeting miR-agshRNAs resulted in a significant and sizable reduction of CNV compared with the non-targeting control. We also demonstrated that single-stranded and self-complementary AAV2.8 vectors efficiently transduce porcine retinal pigment epithelium cells but differ in their transduction characteristics and retinal safety. Collectively, our data demonstrated a robust anti-angiogenic effect of VEGFA-targeting miR-aghsRNAs in a large translational animal model, thereby suggesting AAV-based delivery of anti-VEGFA RNAi therapeutics as a valuable tool for the management of nAMD.

SUBMITTER: Haldrup SH 

PROVIDER: S-EPMC11007540 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Subretinal AAV delivery of RNAi-therapeutics targeting <i>VEGFA</i> reduces choroidal neovascularization in a large animal model.

Haldrup Silja Hansen SH   Fabian-Jessing Bjørn K BK   Jakobsen Thomas Stax TS   Lindholm Anna Bøgh AB   Adsersen Rikke L RL   Aagaard Lars L   Bek Toke T   Askou Anne Louise AL   Corydon Thomas J TJ  

Molecular therapy. Methods & clinical development 20240322 2


Neovascular age-related macular degeneration (nAMD) is a frequent cause of vision loss among the elderly in the Western world. Current disease management with repeated injections of anti-VEGF agents accumulates the risk for adverse events and constitutes a burden for society and the individual patient. Sustained suppression of VEGF using gene therapy is an attractive alternative, which we explored using adeno-associated virus (AAV)-based delivery of novel RNA interference (RNAi) effectors in a p  ...[more]

Similar Datasets

| S-EPMC9379329 | biostudies-literature
| S-EPMC4711821 | biostudies-literature
| S-EPMC5723362 | biostudies-literature
| S-EPMC7396176 | biostudies-literature
| S-EPMC5846441 | biostudies-literature
| S-EPMC6393707 | biostudies-literature
| S-EPMC7408710 | biostudies-literature
| S-EPMC4445610 | biostudies-literature
| S-EPMC9988861 | biostudies-literature
| S-EPMC6745701 | biostudies-literature